Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel Wight

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|July 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in AustraliaStephen P Mulligan, Philip A Thompson, Joel Wight, et al.
European Journal of Haematology|May 3, 2018
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabineAshvind Prabahran, Mark Tacey, Shaun Fleming, et al.
Haematologica|March 21, 2024
Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillanceJoel Wight, Piers Blombery, Jennifer Lickiss, et al.
Hemasphere|June 9, 2026
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyChan Y Cheah, Piers Blombery, Amanda Johnston, et al.
Internal Medicine Journal|September 17, 2021
Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceJoel Wight, Nada Hamad, Belinda A Campbell, et al.
Hemasphere|November 15, 2019
A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AMLAnthony P Schwarer, Jason Butler, Kathryn Jackson, et al.
Internal Medicine Journal|June 17, 2024
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma AllianceMasa Lasica, Mary A Anderson, Alex Boussioutas, et al.
British Journal of Haematology|March 14, 2024
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance studyKate Manos, Leonid Churilov, Andrew Grigg, et al.
Leukemia|March 11, 2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP studyKate Manos, Geoffrey Chong, Colm Keane, et al.
Haematologica|April 2, 2024
<i>Erratum</i> to: Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromesPiers Blombery, Lucy Fox, Georgina L Ryland, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|July 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in AustraliaStephen P Mulligan, Philip A Thompson, Joel Wight, et al.
European Journal of Haematology|May 3, 2018
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabineAshvind Prabahran, Mark Tacey, Shaun Fleming, et al.
Haematologica|March 21, 2024
Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillanceJoel Wight, Piers Blombery, Jennifer Lickiss, et al.
Hemasphere|June 9, 2026
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyChan Y Cheah, Piers Blombery, Amanda Johnston, et al.
Internal Medicine Journal|September 17, 2021
Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceJoel Wight, Nada Hamad, Belinda A Campbell, et al.
Hemasphere|November 15, 2019
A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AMLAnthony P Schwarer, Jason Butler, Kathryn Jackson, et al.
Internal Medicine Journal|June 17, 2024
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma AllianceMasa Lasica, Mary A Anderson, Alex Boussioutas, et al.
British Journal of Haematology|March 14, 2024
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance studyKate Manos, Leonid Churilov, Andrew Grigg, et al.
Leukemia|March 11, 2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP studyKate Manos, Geoffrey Chong, Colm Keane, et al.
Haematologica|April 2, 2024
<i>Erratum</i> to: Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromesPiers Blombery, Lucy Fox, Georgina L Ryland, et al.
Pageof 3